NL-OMON22796尚未招募不适用
Response assessment in post-transplant lymphoproliferative disorder with 18F-FDG-PET/CT and minimal residual disease monitoring, a multicenter multinational feasibility study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Patients having undergone a SOT or HSCT
- •-Histologically proven CD20+ monomorphic PTLD (with or without EBV association),
排除标准
- •-A complete surgical resection of tumor.
- •-Upfront treatment with external beam radiation therapy.
研究者
相似试验
已完成
不适用
Response assessment of post-transplant lymphoproliferative disorder with 18F-FDG-PET/CT and minimal residual disease monitoring, a multicenter multinational feasibility studypost-transplant lymphoma10025320PTLDNL-OMON48552niversitair Medisch Centrum Groningen30
进行中（未招募）
不适用
Treatment of patients with post-transplant lymphoproliferative disorder (PILD) with a sequential treatment consisting of anti-CD20 antibody rituximab and CHOP + GCSF chemotherapy (including first, second and third amendment).EUCTR2005-000743-29-BEHeads Study Group
进行中（未招募）
不适用
PTLD: Multicentric Retrospective StudyPTLDNCT06422715Fondazione Italiana Linfomi - ETS241
已完成
2 期
Risk Stratified Sequential Treatment for CD20-positive PTLDPosttransplant Lymphoproliferative DisorderPTLDNCT00590447Charite University, Berlin, Germany152
终止
2 期
Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)Post-transplantation Lymphoproliferative DisorderNCT01458548Charite University, Berlin, Germany70